Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.94 as of Tuesday, July 28, 2026.
Forward PE Ratio (18.94) = Close Price ($523.63) / Consensus Forward EPS ($27.87)
FORWARD PE RATIO
18.94
SECTOR MEDIAN · HEALTHCARE
18.59
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+1.86%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$22.23B
Forward PE Ratio
18.94
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| United Therapeutics Corporation (UTHR) | $22.23B | 18.94 |
| Moderna, Inc. (MRNA)vs › | $22.14B | N/A |
| STERIS plc (STE)vs › | $22.45B | 21.42 |
| BioNTech SE (BNTX)vs › | $23.38B | N/A |
| Viatris Inc. (VTRS)vs › | $20.80B | 7.20 |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.72B | 37.06 |
| Waters Corporation (WAT)vs › | $25.02B | 25.56 |
| Labcorp Holdings Inc. (LH)vs › | $25.77B | 16.71 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.52B | 10.85 |
| Incyte Corporation (INCY)vs › | $25.96B | 14.83 |
Trailing P/E
19.5
reported TTM EPS
Forward P/E
18.9
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $27.87 implies +3.0% EPS growth vs the reported trailing $27.05.
At today's $523.63 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $27.87 | $26.08 – $29.74 | 11 | 18.8x |
| 2027-12-31 | $32.84 | $25.48 – $39.99 | 11 | 15.9x |
| 2028-12-31 | $40.36 | $27.96 – $48.91 | 10 | 13.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
